Brown, Lisle/Cummings, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Brown, Lisle/Cummings, Inc.
- $329 Billion
- Q3 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 125 shares of ALNY stock, worth $33,323. This represents 0.01% of its overall portfolio holdings.
Number of Shares
125
Previous 125
-0.0%
Holding current value
$33,323
Previous $30.4 Million
13.18%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
636Shares Held
108MCall Options Held
2.33MPut Options Held
2.15M-
Capital World Investors Los Angeles, CA15MShares$3.99 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.33 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.55 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.66 Billion0.28% of portfolio
-
Baillie Gifford & CO6.03MShares$1.61 Billion1.16% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $32.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...